[HTML][HTML] Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers

S Haddadzadegan, F Dorkoosh… - Advanced drug delivery …, 2022 - Elsevier
The oral administration of therapeutic peptides and proteins is favoured from a patient and
commercial point of view. In order to reach the systemic circulation after oral administration …

Cyclic peptide drugs approved in the last two decades (2001–2021)

H Zhang, S Chen - RSC Chemical Biology, 2022 - pubs.rsc.org
In contrast to the major families of small molecules and antibodies, cyclic peptides, as a
family of synthesizable macromolecules, have distinct biochemical and therapeutic …

On the utility of chemical strategies to improve peptide gut stability

T Kremsmayr, A Aljnabi… - Journal of medicinal …, 2022 - ACS Publications
Inherent susceptibility of peptides to enzymatic degradation in the gastrointestinal tract is a
key bottleneck in oral peptide drug development. Here, we present a systematic analysis of …

Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials

TAS Aguirre, D Teijeiro-Osorio, M Rosa… - Advanced drug delivery …, 2016 - Elsevier
The development of oral dosage forms that allows absorption of therapeutic peptides to the
systemic circulation is one of the greatest challenges for the pharmaceutical industry …

Therapeutic peptides targeting PPI in clinical development: Overview, mechanism of action and perspectives

W Cabri, P Cantelmi, D Corbisiero, T Fantoni… - Frontiers in Molecular …, 2021 - frontiersin.org
Targeting protein-protein interactions (PPIs) has been recently recognized as an emerging
therapeutic approach for several diseases. Up today, more than half a million PPI …

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

DM Brenner, R Fogel, SD Dorn, R Krause… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Two identical, phase 3, randomized, double-blind, placebo-controlled trials
evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome …

Progesterone action in breast, uterine, and ovarian cancers

CH Diep, AR Daniel, LJ Mauro… - Journal of …, 2015 - jme.bioscientifica.com
Progesterone and progesterone receptors (PRs) are essential for the development and
cyclical regulation of hormone-responsive tissues including the breast and reproductive …

The sound of drug delivery: optoacoustic imaging in pharmacology

N Liu, K Mishra, AC Stiel, V Gujrati… - Advanced Drug Delivery …, 2022 - Elsevier
Optoacoustic (photoacoustic) imaging offers unique opportunities for visualizing biological
function in vivo by achieving high-resolution images of optical contrast much deeper than …

A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation

PB Miner Jr, WD Koltun, GJ Wiener… - Official journal of the …, 2017 - journals.lww.com
Objectives: This study assessed the efficacy and safety of plecanatide, a guanylate cyclase-
C (GC-C) agonist and the first uroguanylin analog approved for the treatment of chronic …

Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets

V Yadav, F Varum, R Bravo, E Furrer, D Bojic… - Translational …, 2016 - Elsevier
Ulcerative colitis and Crohn's disease are the 2 major phenotypes of inflammatory bowel
disease (IBD), which are influenced by a complex interplay of immunological and genetic …